Titre : Inositol phosphates

Inositol phosphates : Questions médicales fréquentes

Termes MeSH sélectionnés :

Visual Field Tests
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Inositol phosphates : Questions médicales les plus fréquentes", "headline": "Inositol phosphates : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Inositol phosphates : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-23", "dateModified": "2025-04-17", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Inositol phosphates" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Oses phosphates", "url": "https://questionsmedicales.fr/mesh/D013403", "about": { "@type": "MedicalCondition", "name": "Oses phosphates", "code": { "@type": "MedicalCode", "code": "D013403", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D09.894" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Inositol 1,4,5-trisphosphate", "alternateName": "Inositol 1,4,5-Trisphosphate", "url": "https://questionsmedicales.fr/mesh/D015544", "about": { "@type": "MedicalCondition", "name": "Inositol 1,4,5-trisphosphate", "code": { "@type": "MedicalCode", "code": "D015544", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D09.894.480.350" } } }, { "@type": "MedicalWebPage", "name": "Acide phytique", "alternateName": "Phytic Acid", "url": "https://questionsmedicales.fr/mesh/D010833", "about": { "@type": "MedicalCondition", "name": "Acide phytique", "code": { "@type": "MedicalCode", "code": "D010833", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D09.894.480.700" } } } ], "about": { "@type": "MedicalCondition", "name": "Inositol phosphates", "alternateName": "Inositol Phosphates", "code": { "@type": "MedicalCode", "code": "D007295", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Adolfo Saiardi", "url": "https://questionsmedicales.fr/author/Adolfo%20Saiardi", "affiliation": { "@type": "Organization", "name": "Medical Research Council Laboratory for Molecular Cell Biology, University College London, WC1E6BT, London, UK. Electronic address: a.saiardi@ucl.ac.uk." } }, { "@type": "Person", "name": "Henning J Jessen", "url": "https://questionsmedicales.fr/author/Henning%20J%20Jessen", "affiliation": { "@type": "Organization", "name": "Institute of Organic Chemistry & CIBSS - Centre for Integrative Biological Signalling Studies, University of Freiburg, Freiburg, Germany." } }, { "@type": "Person", "name": "Gabriel Schaaf", "url": "https://questionsmedicales.fr/author/Gabriel%20Schaaf", "affiliation": { "@type": "Organization", "name": "Department of Plant Nutrition, Institute of Crop Science and Resource Conservation, Rheinische Friedrich-Wilhelms-University Bonn, Bonn, Germany. gabriel.schaaf@uni-bonn.de." } }, { "@type": "Person", "name": "Debabrata Laha", "url": "https://questionsmedicales.fr/author/Debabrata%20Laha", "affiliation": { "@type": "Organization", "name": "Medical Research Council Laboratory for Molecular Cell Biology, University College London, WC1E6BT, London, UK." } }, { "@type": "Person", "name": "Stephen B Shears", "url": "https://questionsmedicales.fr/author/Stephen%20B%20Shears", "affiliation": { "@type": "Organization", "name": "Inositol Signaling Section, NIEHS, 111, Alexander Drive, Research Triangle Park, Durham, NC 27709, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "[The ground visual field assessment, using two methods, compared with Goldmann perimetry].", "datePublished": "2022-07-05", "url": "https://questionsmedicales.fr/article/35798620", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jfo.2022.03.018" } }, { "@type": "ScholarlyArticle", "name": "Association Between Longitudinal 10-2 Central Visual Field Change and the Risk of Visual Acuity Loss in Mild-to-Moderate Glaucoma.", "datePublished": "2023-05-10", "url": "https://questionsmedicales.fr/article/37171991", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/IJG.0000000000002236" } }, { "@type": "ScholarlyArticle", "name": "Visual field progression in open-angle glaucoma after refractive corneal ablation surgery.", "datePublished": "2023-01-30", "url": "https://questionsmedicales.fr/article/36715786", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10103-023-03709-1" } }, { "@type": "ScholarlyArticle", "name": "Risk factors for visual field progression in newly diagnosed exfoliation glaucoma patients in Sweden.", "datePublished": "2022-06-24", "url": "https://questionsmedicales.fr/article/35750795", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-022-14962-9" } }, { "@type": "ScholarlyArticle", "name": "Fuzzy clustering of 24-2 visual field patterns can detect glaucoma progression.", "datePublished": "2024-09-04", "url": "https://questionsmedicales.fr/article/39231172", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0309011" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Glucides", "item": "https://questionsmedicales.fr/mesh/D002241" }, { "@type": "ListItem", "position": 3, "name": "Oses phosphates", "item": "https://questionsmedicales.fr/mesh/D013403" }, { "@type": "ListItem", "position": 4, "name": "Inositol phosphates", "item": "https://questionsmedicales.fr/mesh/D007295" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Inositol phosphates - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Inositol phosphates", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-07", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Inositol phosphates", "description": "Comment diagnostiquer un déséquilibre en inositol phosphates ?\nQuels tests sont utilisés pour évaluer les inositol phosphates ?\nLes inositol phosphates sont-ils mesurables dans les tissus ?\nY a-t-il des marqueurs spécifiques pour les inositol phosphates ?\nLes tests génétiques sont-ils utiles pour les inositol phosphates ?", "url": "https://questionsmedicales.fr/mesh/D007295?mesh_terms=Visual+Field+Tests&page=5#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Inositol phosphates", "description": "Quels symptômes sont associés à un déséquilibre en inositol phosphates ?\nLes inositol phosphates affectent-ils la santé mentale ?\nY a-t-il des signes physiques d'un déséquilibre ?\nLes inositol phosphates influencent-ils le métabolisme ?\nPeut-on observer des symptômes neurologiques ?", "url": "https://questionsmedicales.fr/mesh/D007295?mesh_terms=Visual+Field+Tests&page=5#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Inositol phosphates", "description": "Comment prévenir les déséquilibres en inositol phosphates ?\nLes suppléments sont-ils nécessaires pour la prévention ?\nY a-t-il des habitudes de vie à adopter ?\nLes consultations médicales sont-elles importantes ?\nLes facteurs environnementaux influencent-ils les niveaux ?", "url": "https://questionsmedicales.fr/mesh/D007295?mesh_terms=Visual+Field+Tests&page=5#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Inositol phosphates", "description": "Quels traitements existent pour les déséquilibres en inositol phosphates ?\nLes médicaments peuvent-ils aider avec les inositol phosphates ?\nY a-t-il des thérapies alternatives pour les inositol phosphates ?\nComment les changements alimentaires aident-ils ?\nLes traitements sont-ils personnalisés ?", "url": "https://questionsmedicales.fr/mesh/D007295?mesh_terms=Visual+Field+Tests&page=5#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Inositol phosphates", "description": "Quelles complications peuvent survenir avec des déséquilibres ?\nLes inositol phosphates sont-ils liés à des maladies chroniques ?\nY a-t-il des risques pour la santé reproductive ?\nLes complications neurologiques sont-elles fréquentes ?\nLes complications psychologiques sont-elles réversibles ?", "url": "https://questionsmedicales.fr/mesh/D007295?mesh_terms=Visual+Field+Tests&page=5#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Inositol phosphates", "description": "Quels sont les facteurs de risque pour les déséquilibres ?\nL'âge influence-t-il les niveaux d'inositol phosphates ?\nLes maladies métaboliques sont-elles un facteur de risque ?\nLe mode de vie sédentaire est-il un risque ?\nLes facteurs environnementaux jouent-ils un rôle ?", "url": "https://questionsmedicales.fr/mesh/D007295?mesh_terms=Visual+Field+Tests&page=5#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer un déséquilibre en inositol phosphates ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins peuvent mesurer les niveaux d'inositol phosphates dans le corps." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer les inositol phosphates ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests biochimiques et les analyses de métabolites urinaires sont courants." } }, { "@type": "Question", "name": "Les inositol phosphates sont-ils mesurables dans les tissus ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des biopsies peuvent être effectuées pour évaluer les niveaux dans les tissus." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs spécifiques pour les inositol phosphates ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des marqueurs comme l'IP3 peuvent indiquer des déséquilibres dans la signalisation cellulaire." } }, { "@type": "Question", "name": "Les tests génétiques sont-ils utiles pour les inositol phosphates ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent aider à identifier des troubles métaboliques liés aux inositol phosphates." } }, { "@type": "Question", "name": "Quels symptômes sont associés à un déséquilibre en inositol phosphates ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Fatigue, troubles de l'humeur et problèmes métaboliques peuvent survenir." } }, { "@type": "Question", "name": "Les inositol phosphates affectent-ils la santé mentale ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des déséquilibres peuvent être liés à des troubles de l'humeur comme la dépression." } }, { "@type": "Question", "name": "Y a-t-il des signes physiques d'un déséquilibre ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des troubles de la peau ou des problèmes digestifs peuvent apparaître." } }, { "@type": "Question", "name": "Les inositol phosphates influencent-ils le métabolisme ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils jouent un rôle dans la régulation du métabolisme lipidique et glucidique." } }, { "@type": "Question", "name": "Peut-on observer des symptômes neurologiques ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles cognitifs et de la mémoire peuvent être liés à des déséquilibres." } }, { "@type": "Question", "name": "Comment prévenir les déséquilibres en inositol phosphates ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et un mode de vie sain sont essentiels pour la prévention." } }, { "@type": "Question", "name": "Les suppléments sont-ils nécessaires pour la prévention ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Des suppléments peuvent être bénéfiques, surtout en cas de carence alimentaire." } }, { "@type": "Question", "name": "Y a-t-il des habitudes de vie à adopter ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "L'exercice régulier et la gestion du stress peuvent aider à maintenir l'équilibre." } }, { "@type": "Question", "name": "Les consultations médicales sont-elles importantes ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des bilans réguliers peuvent aider à détecter des déséquilibres précocement." } }, { "@type": "Question", "name": "Les facteurs environnementaux influencent-ils les niveaux ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des toxines peut affecter le métabolisme des inositol phosphates." } }, { "@type": "Question", "name": "Quels traitements existent pour les déséquilibres en inositol phosphates ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des suppléments d'inositol et des modifications alimentaires peuvent être recommandés." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils aider avec les inositol phosphates ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Certains médicaments psychotropes peuvent influencer les niveaux d'inositol phosphates." } }, { "@type": "Question", "name": "Y a-t-il des thérapies alternatives pour les inositol phosphates ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des approches comme la phytothérapie peuvent être explorées, mais nécessitent des études." } }, { "@type": "Question", "name": "Comment les changements alimentaires aident-ils ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation riche en fruits et légumes peut améliorer les niveaux d'inositol." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements peuvent être adaptés selon les besoins individuels et les symptômes." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des déséquilibres ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles métaboliques, neurologiques et psychologiques peuvent se développer." } }, { "@type": "Question", "name": "Les inositol phosphates sont-ils liés à des maladies chroniques ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des déséquilibres peuvent être associés à des maladies comme le diabète." } }, { "@type": "Question", "name": "Y a-t-il des risques pour la santé reproductive ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des déséquilibres peuvent affecter la fertilité et la santé reproductive." } }, { "@type": "Question", "name": "Les complications neurologiques sont-elles fréquentes ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles cognitifs peuvent survenir en cas de déséquilibre prolongé." } }, { "@type": "Question", "name": "Les complications psychologiques sont-elles réversibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines peuvent être réversibles avec un traitement approprié et un suivi." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les déséquilibres ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation pauvre, le stress et des antécédents familiaux peuvent augmenter le risque." } }, { "@type": "Question", "name": "L'âge influence-t-il les niveaux d'inositol phosphates ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les niveaux peuvent diminuer avec l'âge, augmentant le risque de déséquilibre." } }, { "@type": "Question", "name": "Les maladies métaboliques sont-elles un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des conditions comme le diabète peuvent affecter le métabolisme des inositol phosphates." } }, { "@type": "Question", "name": "Le mode de vie sédentaire est-il un risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie inactif peut contribuer à des déséquilibres en inositol phosphates." } }, { "@type": "Question", "name": "Les facteurs environnementaux jouent-ils un rôle ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des toxines peut perturber le métabolisme des inositol phosphates." } } ] } ] }

Sources (10000 au total)

Association Between Longitudinal 10-2 Central Visual Field Change and the Risk of Visual Acuity Loss in Mild-to-Moderate Glaucoma.

Faster worsening of 10-2 visual field (VF) was associated with the development of visual acuity (VA) loss in mild-to-moderate glaucoma, suggesting longitudinal 10-2 VF change is associated with the ri... To examine whether longitudinal 10-2 central VF change is associated with the risk of VA loss in glaucoma.... Primary open angle glaucoma and glaucoma suspect eyes with ≥3 years and 5 visits of 10-2 VF examinations were included. Cox proportional hazard modeling with shared frailty was used to evaluate the ha... Among the 252 eyes (148 participants, mean follow-up = 5.8 y), 30 eyes (21 participants, mean follow-up = 4.9 y) developed VA loss. There was no difference in baseline VF between eyes with and without... Faster 10-2 VF MD and hemifield MS worsening are associated with the development of VA loss. Monitoring the longitudinal central 10-degree VF change may suggest that there is impending VA impairment i...

Fuzzy clustering of 24-2 visual field patterns can detect glaucoma progression.

To represent 24-2 visual field (VF) losses of individual patients using a hybrid approach of archetypal analysis (AA) and fuzzy c-means (FCM) clustering.... In this multicenter retrospective study, we classified characteristic patterns of 24-2 VF using AA and decomposed them with FCM clustering. We predicted the change in mean deviation (MD) through super... We identified 16 characteristic patterns (archetypes or ATs) of 24-2 VF from 132,938 VFs of 18,033 participants using AA. The hybrid approach using FCM revealed a lower mean squared error and greater ... A hybrid approach combining AA and FCM to analyze 24-2 VF can visualize VF tests in characteristic patterns and enhance detection of VF progression with lossless decomposition....

Predicting Visual Field Progression by Optical Coherence Tomography Angiography and Pattern Electroretinography in Glaucoma.

Reduced P50-N95 amplitude on pattern electroretinography (PERG) and the presence of microvasculature dropout (MvD) on optical coherence tomography angiography (OCT-A) at baseline were significant fact... We investigated the baseline demographics and ocular characteristics that predict future progression in glaucoma patients, including PERG and OCT-A parameters.... One Hundred forty eyes with open angle glaucoma that were prospectively enrolled and followed up for at least 3 years, and underwent at least 5 serial VF tests were included. Baseline PERG was perform... Of the 140 eyes, 107 (76.4%) were NTG and 57 (40.7%) exhibited glaucoma progression as defined by Humphrey VF GPA. The MD slopes were -0.43±1.11 dB/y in the progressors and 0.59±1.27 dB/y in the nonpr... The presence of MvD and retinal ganglion cell dysfunction by PERG at baseline, DH or central scotoma were significant factors associated with VF progression in predominantly NTG patients. These patien...

Visual field indices in children and adults with comparable retinal nerve fiber layer thickness.

To compare visual field indices in normal children and adults with similar retinal nerve fiber layer (RNFL) thickness on optical coherence tomography (OCT).... This cross-sectional study included 59 eyes of 59 normal children 6-18 years of age compared to normal adults. The children underwent visual field testing on the Humphrey Field Analyzer (HFA) and RNFL... Overall, the MD of children was significantly less than that of the normal adults despite having the same RNFL thickness (-2.42 ± 1.42 dB vs -1.61 ± 1.47 dB [P = 0.006]). When stratified by age, the d... In our study cohort, children <12 years had lower visual field indices than adults. Their visual fields may appear worse than they would for an adult with the same RNFL thickness. Normal children >12 ...

Predicting Visual Field Worsening with Longitudinal OCT Data Using a Gated Transformer Network.

To identify visual field (VF) worsening from longitudinal OCT data using a gated transformer network (GTN) and to examine how GTN performance varies for different definitions of VF worsening and diffe... Retrospective longitudinal cohort study.... A total of 4211 eyes (2666 patients) followed up at the Johns Hopkins Wilmer Eye Institute with at least 5 reliable VF results and 1 reliable OCT scan within 1 year of each reliable VF test.... For each eye, we used 3 trend-based methods (mean deviation [MD] slope, VF index slope, and pointwise linear regression) and 3 event-based methods (Guided Progression Analysis, Collaborative Initial G... Area under the receiver operating characteristic curve (AUC).... The M6 labeled 63 eyes (1.50%) as worsening. The GTN achieved an AUC of 0.97 (95% confidence interval, 0.88-1.00) when trained with M6. Gated transformer networks trained and optimized with the other ... Gated transformer network models trained with OCT data may be used to identify VF worsening. After further validation, implementing such models in clinical practice may allow us to track functional wo... Proprietary or commercial disclosure may be found after the references....